10,000th Patient Receives Treatment with ViewRay’s MRIdian System

September 1, 2020
MRI-Guided Radiation Therapy Brings Cutting-Edge Cancer Treatment to Patients Around the World

CLEVELAND, Sept. 1, 2020 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) announced today that 10,000 patients have been treated to date using
the company’s MRIdian® MRI-Guided Radiation Therapy System, the world’s first system to combine MR imaging with radiation delivery.
Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. This feature, together with other
technical innovations, offers advantages for the delivery of safe and effective radiotherapy. These features include the ability to see the tumor and
surrounding tissue during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments,
continuously track the tumor during treatment, and automatically pause the radiation if the tumor moves outside of the boundary. As a result, the
system is able to deliver high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage.
The world’s first MRI-guided radiation therapy treatment was performed six years ago on January 15, 2014 at Siteman Cancer Center at BarnesJewish Hospital and Washington University School of Medicine in St. Louis, Missouri. Clifford G. Robinson, M.D., was the world’s first radiation
oncologist to treat a patient using MRI-guided radiation therapy.
“I remember the day well,” said Dr. Robinson, professor of Radiation Oncology and chief of service, stereotactic body radiation therapy (SBRT) at
Siteman Cancer Center and Washington University School of Medicine. “The very first patient received treatment for a painful bone metastasis. The
moment after we imaged the patient with the MRIdian, we instantly saw the true extent of tumor involvement, and it became clear to me that this was
going to be a paradigm shift in our field.”
As one of the world’s leading cancer centers, Siteman Cancer Center is known for pioneering the advancement and adoption of innovative
technologies with a focus on improving patient care and outcomes. More than 1,300 patients have been treated on MRIdian at Siteman Cancer
Center, which has utilized both the first-generation cobalt version and second generation MRIdian Linac.
“We’re proud to have played an integral role in the development and implementation of MRI-guided radiation therapy,” said Olga L. Green, Ph.D., chief
of service for MRIgRT and Director of the Medical Physics Residency program at Siteman Cancer Center at Barnes-Jewish Hospital and Washington
University School of Medicine. “The integration of MRI guidance, on-table adaptive radiotherapy, and real-time anatomy targeting has provided us with
opportunities to expand treatment options for our patients over the last six years. This patient treatment milestone was made possible by the
increasing recognition by more and more institutions around the world that this cutting-edge approach has the potential to make a significant impact in
our field.”
MRIdian was invented by ViewRay Founder and Chief Scientific Officer James F. Dempsey, Ph.D. Dr. Dempsey completed his doctorate in nuclear
chemistry at Washington University and his postdoctoral studies, as well as his medical physics residency, in the Department of Radiation Oncology at
Washington University School of Medicine.
“At ViewRay, we have always believed in working to make the impossible possible in order to change the paradigm of care,” said Dr. Dempsey. “This
spirit enabled us to pioneer the MRIdian, not only as the world’s first MRI-guided system, but one which still provides proprietary capabilities to quickly
adapt the therapy and continuously track the tumor during treatment. These powerful innovations have enabled clinicians to deliver higher doses of
radiation to cancer patients with fewer side effects. I am grateful for opportunity to partner with clinicians around the world who are employing MRIdian
to deliver better outcomes in cancer care.”
Currently 38 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus
of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and
presentations. For a list of treatment centers, please visit https://viewray.com/mridian-locator.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary
high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation
oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including
beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements
in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the
rate of new orders, upgrades, and installations, ViewRay’s anticipated future operating and financial performance, and ViewRay’s conference calls to
discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors
include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay’s products, the ability to convert backlog into revenue,
the timing of delivery of ViewRay’s products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts
across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the
ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties
associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a
further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as
well as risks relating to ViewRay’s business in general, see ViewRay’s current and future reports filed with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its Quarterly Reports on Form 10-Q, as updated
periodically with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/10-000th-patient-receives-treatment-with-viewraysmridian-system-301121514.html
SOURCE ViewRay, Inc.
Media Enquiries: Karen Hackstaff, Vice President, Strategy and Brand, ViewRay, Inc., 1-844-MRIdian (674-3426), media@viewray.com; Investor
Relations: Michaella Gallina, Vice President, Chief of Staff, Head of Investor Relations and Communications, ViewRay, Inc., 1-844-MRIdian
(674-3426), investors@viewray.com